Active Biotech AB

251 articles about Active Biotech AB

• Active Biotech AB Interim Report January - September 2012

  11/9/2012

• EXINI and Active Biotech AB Initiate Collaboration, Aiming to Clinically Evaluate the Future of Cancer Treatment

  10/30/2012

• Teva Pharmaceutical Industries Limited Reports Success in Laquinimod Study for Crohn's Disease

  10/22/2012

• Active Biotech AB's Partner Ipsen Initiates a Proof-of-Concept Study With Tasquinimod in Additional Cancer Indications

  10/19/2012

• Active Biotech AB, Ipsen Initiate a Phase II "Switch Maintenance" Trial in Metastatic Castrate-Resistant Prostate Cancer With Tasquinimod

  10/3/2012

• Active Biotech AB's Tasquinimod Biomarker Phase II Data Presented at ESMO 2012

  10/1/2012

• Active Biotech AB to Present at the Rodman & Renshaw Annual Global Investment Conference

  9/6/2012

• Active Biotech AB Interim Report January - June 2012

  8/10/2012

• Teva Pharmaceutical Industries Limited/Active Biotech AB MS Pill Accepted for Review in Europe

  7/17/2012

• Active Biotech AB’s and Ipsen’s Tasquinimod Shows Encouraging Overall Survival Improvement in Castrate Resistant Prostate Cancer

  6/4/2012

• Active Biotech AB, Ipsen Present Encouraging OS Data from Tasquinimod Phase II Study in CRPC

  6/4/2012

• Active Biotech AB to Present at the Jefferies and Co. 2012 Global Healthcare Conference

  5/31/2012

• Active Biotech AB Invites to

  5/29/2012

• 600 Patients Recruited in Active Biotech AB's and Ipsen's Tasquinimod Clinical Phase III Study

  5/21/2012

• Active Biotech AB and Ipsen to Present Tasquinimod Phase II Overall Survival data at the 2012 American Society of Clinical Oncology Annual Meeting

  5/18/2012

• Annual General Meeting of Active Biotech AB

  5/11/2012

• Evotec AG and Active Biotech AB Extend and Expand Medicinal Chemistry Collaboration

  4/26/2012

• Active Biotech AB Interim Report January - March 2012

  4/26/2012

• Active Biotech AB: Notice of Annual General Meeting of Shareholders

  4/11/2012

• Active Biotech AB Rises After "Buy" Recommendation

  3/16/2012